Completed
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
NCT00554515
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +18 more
- Locations
-
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States